

Paul Getz, MD

Dundee Dermatology. 1201 Water Tower Road. West Dundee IL. 60118-3330
T 847.851.8888 F 847.851.8889

profile

Over three decades of experience in multiple facets of dermatology; medical, surgical, and aesthetic.

experience

Medical Director, **Dundee Dermatology**
1201 Water Tower Road; West Dundee, Illinois May, 2003-present

Associate Physician, **Leone Dermatology Center**
3060 N Arlington Heights Road; Arlington Heights, IL June, 1999-2003

Staff Physician, **Medical Arts Associates**
Moline, Illinois Oct, 1997-June, 1999

Senior Physician, **The Permanente Medical Group**
Richmond, California January, 1982-1997

appointments

Chief, Department of Dermatology
Kaiser Foundation Hospital, Richmond Medical Center
Richmond, California 1988-1997

Clinical Instructor
Department of Dermatology
University of California, San Francisco 1982-1995

Staff President 1989-1990
Staff Vice President 1987-1988
Kaiser Foundation Hospital, Richmond Medical Center

Chief Resident in Dermatology
Cook County Hospital, Chicago 1980-1981

Paul Getz, MD

curriculum vitae

page - 2 -

certification	Diplomate , American Board of Dermatology Recertified , American Board of Dermatology	1981 2009
education	Doctor of Medicine , University of Illinois, Chicago Bachelor of Science , University of Illinois, Urbana	1977 1970
training	Residency, Dermatology ; Cook County Hospital, Chicago Rotating Internship ; Cook County Hospital, Chicago	1981 1978

affiliations	Fellow, American Academy of Dermatology Fellow, American Society for Dermatologic Surgery Fellow, American Society for Laser Medicine and Surgery Member, Chicago Dermatologic Society
---------------------	---

clinical research as principal investigator:

12/2017 – present	phase 3: a randomized, double-blind, vehicle-controlled study to evaluate the efficacy and safety of topical administration of FMX101 for 12 weeks in the treatment of moderate-to-severe acne vulgaris
02/2017 – present	phase 2A: randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of PF-06700841 in subjects with moderate to severe plaque psoriasis
04/2016 – present	phase 3: BI 655066 (risankizumab) versus placebo in a multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment
04/2016 – 10/2017	phase 3: an open-label study of dupilumab in patients with atopic dermatitis who participated in previous dupilumab clinical trials
04/2016 – 06/2017	phase 2B: randomized, double blind, placebo controlled, parallel, multicenter, dose-ranging, study to evaluate the efficacy and safety profile of PF-04965842 in subjects with moderate to severe atopic dermatitis.

Paul Getz, MD

curriculum vitae

page - 3 -

- 06/2015 - 04/2016 phase 2: A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of orally administered DS107G to patients with moderate to severe atopic dermatitis
- 05/2015 – present phase 3: multicenter, randomized, double-blind, parallel-group, study followed by a dose-blind period and all open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis
- 02/2015 – 09/2015 phase 2: randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of pf-04965842 in subjects with moderate to severe psoriasis
- 12/2014 – 12/2016 phase 3: randomized, double-blind, placebo-controlled study to demonstrate the efficacy and long term safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis
- 08/2014– 08/2016 phase 3: randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab and humira in patient with moderate to severe chronic plaque-psoriasis
- 03/2013 – present phase 3: randomized, placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous SCH 900222/MK-3222, followed by an optional long-term safety extension study, in subjects with moderate-to-severe chronic plaque psoriasis
- 08/2012 – 11/2015 phase 3: study to evaluate the efficacy, safety, and effect of withdrawal and retreatment with brodalumab in subjects with moderate to severe plaque psoriasis
- 05/2011 – 08/2016 phase 3: multi-site, open-label study of the long term safety and tolerability of 2 oral doses of tofacitinib in subjects with moderate to severe chronic plaque psoriasis
- 02/2011 – 09/2015 phase 3: multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast in subjects with moderate to severe plaque psoriasis
- 08/2013 – 12/2014 phase 2b: multi-site, randomized, double-blind, vehicle-controlled, parallel-group study of the efficacy, safety, local tolerability and pharmacokinetics of 2 dose strengths and 2 regimens of tofacitinib ointment in subjects with chronic plaque psoriasis.

Paul Getz, MD

curriculum vitae

page - 4 -

- 07/2013 – 12/2014 phase 2a: randomized, double-blind, placebo-controlled, multicenter study to assess MEDI8968 in hidradenitis suppurativa
- 07/2011 – 12/2013 phase 3, multi-site, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of 2 oral doses of tofacitinib in subjects with moderate to severe chronic plaque psoriasis
- 06/2010 – 04/2011 phase 2: dose ranging and efficacy study of ixekizumab (an anti-il-17 antibody) in patients with moderate-to-severe psoriasis
- 01/2009 – 12/2010 phase 3: efficacy and safety of alitretinoin in the treatment of severe chronic hand eczema refractory to topical therapy
- 06/2008 – 08/2009 phase 2b: multicenter, randomized, double-blind, parallel-group, placebo-controlled trial evaluating the efficacy and safety of dose regimens with oral tofacitinib in the treatment of subject with chronic plaque psoriasis
- 05/2008- 06/2009 phase 3: 12-week double-blind, multi-center, randomized study designed to evaluate the efficacy and safety of briakinumab versus Enbrel versus placebo in the treatment of moderate to severe plaque psoriasis
- 02/2008 – 11/2011 open registry: multicenter, patients with psoriasis who are candidates for systemic therapy including biologics
- 02/2008 – 08/2009 phase 3: multicenter, randomized, double-blind, placebo-controlled study comparing the safety and efficacy of two dosing regimens of briakinumab to placebo in subjects with moderate to severe chronic plaque psoriasis
- 08/2007 – 02/2012 phase 3: multicenter, open-label study to assess the efficacy and safety of infliximab therapy in patients with plaque psoriasis who had an inadequate response to Enbrel
- 12/2006 – 04/2007 phase 4: clinical evaluation of cleniziderm for the topical treatment of patients with mild to moderate facial acne vulgaris
- 04/2007 – 10/2007 phase 3: randomized, double-blind, placebo-controlled, parallel design, multi-site clinical study to evaluate the Bioequivalence of calcipotrene ointment 0.005% to DOVONEX® 0.005% in patients with moderate to severe plaque psoriasis
- 02/2004 - 10/2004 phase 3: multicenter, open label, prospective study to evaluate the effectiveness and safety of etanercept in the treatment of subjects with psoriasis.

Paul Getz, MD

curriculum vitae

page - 5 -

- 06/2003 – 06/2004 phase 4: assessment and tracking of long-term alefacept (LFA-3/IgG1 fusion protein) safety
- 09/2003- 04/2004 phase 3: multicenter, open-label to observe effect of etanercept on joint and skin disease in subjects with psoriatic arthritis
- 09/2003 - 05/2004 phase 3b: open-label, multicenter study to evaluate the safety of 1.0-mg/kg subcutaneously administered efalizumab in adults with moderate to severe plaque psoriasis, including those who are receiving concomitant antipsoriatic therapies or have recently transitioned from systemic therapies.